Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd)

NCT05458401 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT05458401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05458401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd)
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
November 11, 2022
Completion date
December 1, 2023
Enrollment
256 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer